Search Results 441-450 of 1568 for ai绘图官网,ai智能公司官网,ai翻译官官网,免费ai写作官网,ai生成网址,等欢迎访问豌豆Ai站群搜索引擎系统官方网站:www.wd.chat

  1. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  2. Hancheng Cai, Ph.D. - Doctors and Medical Staff - Mayo Clinic

    Hancheng Cai, PhD, is a radiochemist and molecular imaging scientist. My clinical work focus on FDA cGMP PET drug production facility implementation and ...

  3. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  4. Funding - Neuromotor Behavior and Locomotion: Farwa Ali - Mayo Clinic Research

    INVESTIGATOR & ROLE. GRANT TITLE. FUNDING SOURCE. DURATION. Farwa Ali, M.B.B.S. Principal Investigator, Mechanisms of Gait and Balance Impairment in ...

  5. Breast cancer - Doctors and departments - Mayo Clinic

    Analyzing the genetic makeup of breast cancer cells to understand how DNA changes affect response to cancer treatments and personalize treatment options.

  6. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  7. An Extension Study to QTI571A2301 to Evaluate the Long-Term Safety, Tolerability and Effectiveness of Imatinib in Severe Pulmonary Arterial Hypertension - Mayo Clinic

    About this study. The purpose of this extension study is to provide data on the long-term safety, tolerability, and efficacy of imatinib in the treatment of ...

  8. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  9. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  10. Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma - Mayo Clinic

    Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual ...